Credit Suisse Ag Humacyte, Inc. Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$2.02 - $3.62 $30,756 - $55,118	15,226 Added 35.22%	58,455 $123,000
Q3 2022 Nov 10, 2022	BUY	$1.22 - $5.14 $137 - $580	113 Added 0.26%	43,229 $140,000
Q2 2022 Aug 12, 2022	BUY	$3.21 - $7.86 $18,065 - $44,236	5,628 Added 15.01%	43,116 $138,000
Q1 2022 May 16, 2022	BUY	$4.65 - $7.4 $10,881 - $17,316	2,340 Added 6.66%	37,488 $264,000
Q4 2021 Feb 14, 2022	BUY	$7.25 - $11.6 $254,823 - $407,716	35,148 New	35,148 $255,000

172

41M

553K

942K

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $365M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.